ISSN:
1569-8041
Keywords:
cisplatin
;
combination chemotherapy
;
phase I
;
phase II
;
small-cell lung cancer
;
topotecan
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background:The aim was to define the MTD of topotecan (TPT) givenbefore cisplatin in patients with previously untreated SCLC. Patients and methods:Alternating cycles A and B to a total of 6cycles were given. Cycle A: TPT days 1–5 and cisplatin (50mg/m2) day 5. Cycle B consisted of teniposide, carboplatin,vincristine, and cisplatin. TPT was escalated at doses 0.75, 1.0, 1.25, and1.5 mg/m2. DLT was defined for the first cycle as grade 4neutropenia with fever or when lasting 〉7 days, or grade 4thrombocytopenia. Results:Fifteen patients with limited disease and six patientswith extensive disease were included. No episodes of DLT were recorded in thefirst cycles A and consequently 1.5 mg/m2 was defined as MTD. At1.5 mg/m2 (11 patients, 30 cycles), four and three episodes ofgrade 4 thrombocytopenia and neutropenia lasting more than seven days occurredin subsequent cycles A. Thrombocytopenia and anaemia were cumulative as morecycles were administrated. Non-hematological toxicity was mild. The responserate was 86% (95% confidence interval (95% CI):64%–97%) with 33% (95% CI:15%–57%) achieving CR. Conclusions:1.5 mg/m2 TPT can be delivered safely with50 mg/m2 cisplatin on day 5 in patients with previously untreatedSCLC.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008393512479
Permalink